Vivitrol (Naltrexone Microspheres) Patent Expiration, LOE Window & CMS Spending

Vivitrol (Naltrexone Microspheres) by Alkermes: FDA Orange Book LOE 2029-10-15, 7 AB generics, $435.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlkermes
FDA Application & PathwayN021897 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-10-15
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$435.5M
2024 Medicare Part D Spend$73.1M
2024 Medicaid Spend$362.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Alkermes across sibling Meru public-data platforms.